Mark A. Schlossberg
Keine laufenden Positionen mehr
Profil
Mark A.
Schlossberg served as an Independent Director at ImmunoCellular Therapeutics Ltd.
from 2015 to 2017.
He was a Director at Angiologix, Inc. and a Vice President at Amgen, Inc. from 2004 to 2011.
He also worked as a Principal at R.J.
Reynolds Tobacco Holdings, Inc. and as a Vice President-Law at Medtronic Trading Ltd.
Additionally, he served as the Secretary, Senior Vice President & General Counsel at Impax Laboratories LLC from 2012 to 2018 and as the Secretary, Senior VP-Legal & General Counsel at Cytokinetics, Inc. from 2011 to 2022.
Schlossberg received his undergraduate degree from the University of Southern California and his graduate degree from Emory University School of Law.
Ehemalige bekannte Positionen von Mark A. Schlossberg
| Unternehmen | Position | Ende |
|---|---|---|
| CYTOKINETICS, INCORPORATED | General Counsel | 13.05.2022 |
Impax Laboratories LLC
 Impax Laboratories LLC Pharmaceuticals: MajorHealth Technology Impax Laboratories LLC operates as a technology based specialty pharmaceutical company. It engages in the development, manufacture, and marketing of controlled-release and niche generics. The company was founded on December 14, 1999 and is headquartered in Bridgewater, NJ. | General Counsel | 01.05.2018 |
| EOM PHARMACEUTICALS HOLDINGS, INC. | Direktor/Vorstandsmitglied | 15.08.2017 |
| AMGEN INC. | Corporate Officer/Principal | 01.05.2011 |
R.J. Reynolds Tobacco Holdings, Inc.
 R.J. Reynolds Tobacco Holdings, Inc. TobaccoConsumer Non-Durables R.J. Reynolds Tobacco Holdings, Inc. manufactures and markets cigarettes and tobacco products. The company was founded in 1970 and is headquartered in Winston-Salem, NC. | Corporate Officer/Principal | - |
Ausbildung von Mark A. Schlossberg
| University of Southern California | Undergraduate Degree |
| Emory University School of Law | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| CYTOKINETICS, INCORPORATED | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Impax Laboratories LLC
Impax Laboratories LLC Pharmaceuticals: MajorHealth Technology Impax Laboratories LLC operates as a technology based specialty pharmaceutical company. It engages in the development, manufacture, and marketing of controlled-release and niche generics. The company was founded on December 14, 1999 and is headquartered in Bridgewater, NJ. | Health Technology |
Angiologix, Inc.
 Angiologix, Inc. Electronic Equipment/InstrumentsElectronic Technology Angiologix, Inc. provides cardiovascular diagnostic products. It serves physician-specialists, cardiologists, vascular medicine, endocrinologists, and primary care physicians. The company was founded in 2007 and is headquartered in Mountain View, CA. | Electronic Technology |
| Medtronic Trading Ltd. | |
Diageo India Pvt Ltd.
 Diageo India Pvt Ltd. Beverages: AlcoholicConsumer Non-Durables Part of Diageo Plc, Diageo India Pvt Ltd. is an Indian company that manufactures and wholesales wines and spirits. The company is based in Mumbai, India. The company was founded in 1993 by Deepak Shashibhusan Roy. Abanti Sankaranarayanan has been the CEO of the company since 2010. | Consumer Non-Durables |
R.J. Reynolds Tobacco Holdings, Inc.
R.J. Reynolds Tobacco Holdings, Inc. TobaccoConsumer Non-Durables R.J. Reynolds Tobacco Holdings, Inc. manufactures and markets cigarettes and tobacco products. The company was founded in 1970 and is headquartered in Winston-Salem, NC. | Consumer Non-Durables |
ImmunoCellular Therapeutics Ltd.
 ImmunoCellular Therapeutics Ltd. BiotechnologyHealth Technology ImmunoCellular Therapeutics, Ltd. is a clinical-stage pharmaceutical company, focused on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ. | Health Technology |
